A Phase Ib/II, Multicenter Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF Mutant Melanoma
To find the highest safe dose of LEE011 with LGX818 (the study drugs) in subjects with melanoma and to study the safety and effects of the study drugs.
1. Male or female 18 years or older
2. Locally advanced or metastatic melanoma with documented BRAF V600 mutation.
3. Tumor sample available for molecular testing
4. Other criteria also apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression, unacceptable side effects, or participant's decision to withdraw from the study.
Knight Clinical Trials Information Line
Novartis Pharmaceutical Corporation